Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain

Jo Kitawaki; Izumi Kusuki; Kaoruko Yamanaka; Izumi Suganuma

doi:10.1016/j.ejogrb.2011.03.012

Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain

Jo Kitawaki, Izumi Kusuki, Kaoruko Yamanaka, Izumi Suganuma

European journal of obstetrics, gynecology, and reproductive biology · 2011 · vol. 157(2) , pp. 212–216 · doi:10.1016/j.ejogrb.2011.03.012 · PMID:21474232 · W1969971130

article OA: closed CC0 ⤵ 50 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study evaluated the efficacy of dienogest maintenance therapy after GnRH agonist treatment for endometriosis-associated pelvic pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715mesh:D017699endometriosis

MeSH descriptors

Buserelin Endometriosis Gonadotropin-Releasing Hormone Hormone Antagonists Nandrolone Pelvic Pain Pelvic Pain Adult Buserelin Dose-Response Relationship, Drug Drug Therapy, Combination Endometriosis Female Gonadotropin-Releasing Hormone Hormone Antagonists Humans Middle Aged Nandrolone Nandrolone Pelvic Pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis via openalex
A randomised controlled trial comparing GnRH antagonist Cetrorelix with GnRH agonist Leuprorelin for endometrial thinning prior to transcervical resection of endometrium via openalex
Chronic pelvic pain in women: etiology, pathogenesis and diagnostic approach via openalex
Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression via openalex
Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex
Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study via openalex
Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
Endometriosis: Treatment Strategies via openalex
High-dose pilot study with the novel progestogen dienogestin patients with endometriosis via openalex
Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin- releasing hormone agonist via openalex
Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain via openalex
New Progestogens via openalex
Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells via openalex
Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex
The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro via openalex
Treatment of deeply infiltrating endometriosis via openalex
Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas via openalex
W6723391054 via openalex
W1618997004 via openalex
W2042374015 via openalex
W2045458073 via openalex
W2080251208 via openalex
W2101417341 via openalex
W2497131907 via openalex
W4285719527 via openalex
W10868991 via openalex

Cited by (50)

Source provenance

europepmc: last seen: 2026-06-04T01:30:01.192114+00:00
openalex: last seen: 2026-06-04T00:00:01.174412+00:00
pubmed: last seen: 2026-05-13T22:16:48.482574+00:00

License: CC0 · commercial use OK

[1] A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis via openalex

[2] A randomised controlled trial comparing GnRH antagonist Cetrorelix with GnRH agonist Leuprorelin for endometrial thinning prior to transcervical resection of endometrium via openalex

[3] Chronic pelvic pain in women: etiology, pathogenesis and diagnostic approach via openalex

[4] Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression via openalex

[5] Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex

[6] Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex

[7] Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study via openalex

[8] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex

[9] Endometriosis: Treatment Strategies via openalex

[10] High-dose pilot study with the novel progestogen dienogestin patients with endometriosis via openalex

[11] Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin- releasing hormone agonist via openalex

[12] Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain via openalex

[13] New Progestogens via openalex

[14] Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells via openalex

[15] Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex

[16] The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro via openalex

[17] Treatment of deeply infiltrating endometriosis via openalex

[18] Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas via openalex

[19] W6723391054 via openalex

[20] W1618997004 via openalex

[21] W2042374015 via openalex

[22] W2045458073 via openalex

[23] W2080251208 via openalex

[24] W2101417341 via openalex

[25] W2497131907 via openalex

[26] W4285719527 via openalex

[27] W10868991 via openalex